Key Investor Signals
Raised an oversubscribed $7.14M seed led by Felicis and Refactor, with Y Combinator participating
Granza Bio closed a $7.14 million oversubscribed seed round led by Felicis and Refactor, with , Pioneer Fund, and Oxford Angel Fund also participating.
Co-founder and CSO named to Forbes 30 Under 30 Europe and selected as a Schmidt Science Fellow.
Ashwin Jainarayanan made the 2025 Forbes 30 Under 30 Europe list for Science and Healthcare. He is also a 2024 Schmidt Science Fellow, one of 32 chosen worldwide.
Selected for Y Combinator's Winter 2024 batch.
Granza Bio joined Y Combinator's Winter 2024 batch with Jared Friedman as YC primary partner.
Other Positive Signals
- Mentored by AstraZeneca at Oxford. Granza Bio joined the first cohort at Oxford.
- Published peer-reviewed particle-biology research in PNAS in 2025.
- Joined the University of Oxford's BioEscalator in April 2024.
Team
Ashwin Nandakumar
CEO and Co-Founder
- Earned a in Oncology at the University of Oxford.
- Worked as a Cancer Research UK postdoctoral researcher at Oxford and at the Institute of Cancer Research, London.
- Co-authored a 2021 Cancer Research paper on IGF blockade and replication stress in cancer cells.
- Co-founded OncoAssign, a cancer diagnostics venture matching patients to treatment using biomarker data.
Ashwin Jainarayanan
CSO and Co-Founder
- Earned a DPhil in Interdisciplinary Bioscience at Oxford's .
- Characterised the cytotoxic particles released into the , the biology Granza Bio is built on.
- Engineered cytotoxic T cells to release synthetic extracellular particles that target and kill cancer cells.
- First-authored a 2023 peer-reviewed paper comparing methods for isolating attack particles from killer T cells.
Product
Granza Bio is developing engineered protein shells that direct therapeutic cargo to selected tissues. Its lead program packages synthetic versions of attack particles, the natural killing entities released by cytotoxic immune cells, into an off-the-shelf cancer therapy.
Synthetic attack particles
Attack particles carry , which opens the target-cell membrane, and granzymes, which trigger cell death. Granza Bio's first program aims to direct this mechanism against cancer cells.
Precision delivery shells
Each engineered shell is fitted with a targeting receptor that determines where its cargo is delivered. The platform is designed around tissue targeting, immune compatibility and stability.
Platform for multiple cargos
The shells are intended to carry attack particles, RNA or proteins. A library of shells targeting different tissues could support Granza Bio's internal programs and external licensing partnerships.
Market Overview
Granza Bio enters a large oncology market in which precise delivery remains a central constraint. Global cancer incidence reached 20.6 million new diagnoses in 2024 and is projected to rise to 34.4 million by 2050. Potent immune-based therapies can destroy tumor cells, but their delivery must be controlled to limit exposure to healthy tissue.
Commercial demand is established across immunotherapy and targeted drug delivery. The global cancer immunotherapy market was valued at $153.3 billion in 2025, while the antibody-drug conjugate market reached $14.5 billion. Granza Bio sits at the intersection of these categories, using engineered shells to direct immune-derived killing mechanisms and other therapeutic cargo to specific tissues.
Annual new cancer diagnoses from 2024 to projected 2050.
Projected growth from 2025 to 2033.
Global sales generated in 2025.
Projected growth from 2025 to 2033.
Comparable Outcomes
Seagen
Seagen developed antibody-drug conjugates that link a tumor-targeting antibody to a cell-killing payload. It brought four cancer therapies to market, including Adcetris, Padcev and Tivdak. Seagen went public as Seattle Genetics in 2001 at $7 a share, raising $49 million. Pfizer acquired it in 2023 for $229 a share in cash, valuing the transaction at about $43 billion.
Avidity Biosciences
Avidity developed Antibody Oligonucleotide Conjugates, which use antibodies to deliver RNA therapies into muscle tissue. it was valued for a delivery platform capable of supporting multiple programs rather than a single drug candidate. Avidity went public in 2020 at $18 a share, raising $298.1 million. Novartis acquired it in 2026 for $72 a share in cash, valuing the company at approximately $12 billion.
Kite Pharma
Kite developed CAR-T therapies by engineering a patient’s T cells to recognize and kill cancer cells. Its success established the value of potent immune-cell killing in oncology. Kite went public in 2014 at $17 a share, raising net proceeds of $134.1 million. Gilead acquired the company in 2017 for $180 a share in cash, or approximately $11.9 billion in total.
Have a question about Granza Bio?
Ask DealBio. We may research the answer or share selected questions with the company.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.